Sernova (TSE:SVA) PT Lowered to C$1.50

Sernova (TSE:SVA) had its price objective cut by Leede Financial from C$3.00 to C$1.50 in a research note released on Friday morning, BayStreet.CA reports. They currently have a speculative buy rating on the stock. Leede Financial also issued estimates for Sernova’s FY2027 earnings at ($0.02) EPS.

Sernova Stock Performance

Shares of SVA stock opened at C$0.25 on Friday. The stock has a fifty day moving average price of C$0.27 and a 200 day moving average price of C$0.37. The company has a debt-to-equity ratio of 16.55, a quick ratio of 18.11 and a current ratio of 0.62. The stock has a market cap of C$79.48 million, a PE ratio of -1.88 and a beta of 1.38. Sernova has a 1 year low of C$0.20 and a 1 year high of C$0.83.

Sernova (TSE:SVA) last released its quarterly earnings results on Friday, June 14th. The company reported C($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of C($0.03). Sell-side analysts forecast that Sernova will post -0.08 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Steven Sangha sold 930,000 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of C$0.24, for a total value of C$223,200.00. Insiders have acquired 359,600 shares of company stock worth $92,771 over the last ninety days. 12.98% of the stock is currently owned by insiders.

About Sernova

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.